

**FDI Proposals approved by Department of Pharmaceuticals (Status as on 31.03.2018)**

S. No.	Proposal No.	Name of the applicant	Gist of the proposal	Sector	FDI (Rs. Cr)
1.	4463	M/s Fanem Medical Devices India Private Limited	Issuance of 1,90,045 equity shares of Rs. 10 at a premium of Rs. 126.95/- to Fanem Brazil against the import payables to the tune of USD 3,91,502.87/ Rs. 2,60,27,110.80 from Fanem Brazil.	Pharmaceuti cals	2.60
2.	4551	M/s Recipharm Participation BV, Netherlands	For increase in FDI from 74% to 100% in Nitin Lifesciences Limited (NLL).	Pharmaceuti cals	260
3.	4485	M/s Reckitt Benckiser (India) Private Limited	Increase in equity holding from 49 percent to 100 percent of the equity of M/s Reckitt Benckiser Scholl India Private Limited by transfer of 2,55,00,000 shares from M/s New Bridge Holdings B.V., Netherlands to M/s Reckitt Benckiser (India) Private Limited.	Pharmaceuti cals	Nil.
4.	4141	M/s VMG Pharmaceutical Pvt. Ltd.	Ex-post facto approval for allowing FDI in the company w.e.f 08/11/2011, to regularize the contravention made under Foreign Direct Investment under FEMA as the company has already received FDI to the extent of Rs. 52,19,993.22 without FIPB approval and allotted shares to Non-Residents after 8 <sup>th</sup> November, 2011.	Pharmaceuti cals	Nil
5.	4509	M/s Amneal Oncology Private Limited	Transfer of shares of Amneal Oncology Private Limited from Amneal Pharmaceuticals Private Limited, an Amneal group company incorporated in India to New Singapore Entity, subsidiary of Amneal Pharmaceuticals Holding GmbH, proposed to be incorporated under the laws of Singapore	Pharmaceuti cals	Nil
6.	4467	M/s Meghdoot Chemicals Limited	(i) Acquiring 96,000 equity shares (100%) of face value of Rs. 100 each @ Rs. 200/- per equity shares for a total amount of Rs. 1.92 crores of M/s Meghdoot Chemicals Limited, Mumbai from M/s Meghdoot Chemicals Cor. Limited, Belize. And (ii) Subscription by foreign investor for issuance of 4 Lakh fresh equity shares having a face value of Rs. 100 each @ Rs. 200/- per equity shares amounting to Rs. 8 crores.	Pharmaceuti cals	9.92
7.	4523	M/s Otsuka Pharmaceutical India Private Limited	The proposal is for acquiring entire 20% equity of Otsuka Pharmaceutical India Private Limited held by Claris by Otsuka, Japan (applicant).	Pharmaceuti cals	129

PK

8.	4512	M/s Raks Pharma Private Limited	i) Ex-Post facto approval for infusion of funds by non residents and inter group transfer of shares (executed transactions) and (ii) Proposed restructuring through transfer of 100% shareholding of Anmeal Singapore in Raks Pharma to New Singapore Entity without any change in the ultimate control of the Company.	Pharmaceuti cals	Nil
9.	4185	M/s Stride Shasun Limited	(i) Grant of 10,000 ESOPs on 07.02.2014, which have been already exercised by Shri Mohan Ram Prasad on 04.03.2015 by paying a price of Rs. 322.30 per share amounting to Rs. 32,23,000; and (ii) Allowing Shri Mohan Ram Prasad to exercise/ purchase remaining 40,000 ESOPs at an exercise price of Rs. 322.30 per equity share under the Strides Shasun Ltd's ESOP Scheme 2011.	Pharmaceuti cals	1.28
10.	4433	M/s BioMerieux India Private Limited	(i) Ex Post-facto approval for acquisition of 10% shareholding (belonging to resident shareholder Dr. K.I. Varaprasad Reddy) in RAS Lifesciences Private Limited by M/s bioMerieux India Pvt. Ltd. (the applicant) in March 2015 (that increased total foreign shareholding by BIPL to 70% of the equity capital of RAS Lifesciences). (ii) Prior approval for increasing shareholding of BIPL in RAS from 70% to 100% by acquiring remaining 30% shares from the resident shareholders Mr. Shesheer Kumar and Ms. Rachana Tripathi.	Pharmaceuti cals	Nil
11.	4501	M/s Amneal Pharmaceuticals Private Limited	Ex-post facto approval for the FDI of Rs. 313.80 crore infused by the foreign collaborator/investor and internal transfer of shares.	Pharmaceuti cals	Nil
12.	4629	M/s Veego Pharma LLC	M/s Veego Pharma LLC, USA (formerly known as Gavis Pharma LLC), a brownfield pharmaceutical company sought approval for enhancing its shareholding in M/s Wintac Limited an established Brownfield Pharma Company having a fairly strong presence in developing new drug products through regulatory filing especially in USA. M/s. Veego proposes to enhance its shareholding in Wintac upto 75 percent by way of investment from time to time of upto Rs. 150 Crores.	Pharmaceuti cals	76.25

✓

13.	4234	M/s Celon Laboratories Limited	For amendment to FIPB approval letters No. FCII 58(2013)/111(2013) dated August 3, 2015 and October 16, 2015. For amendment to two of the conditions in FIPB approvals accorded vide FIPB approval letters No. FCII 58(2013)/111(2013) dated August 3, 2015 (p 228-227/c) regarding downstream investment through internal accruals only and condition in approval dated October 16, 2015 regarding compounding by RBI for the existing foreign equity of 63.09% against the approved foreign equity of 54.26%.	Pharmaceuti cals	Nil
14.	4618	M/s ESEN Lifesciences Private Limited	For transfer of all the 5000 shares of the company from existing shareholders to a non-resident company, M/s DXN Holdings BHD, Malaysia for a consideration amount of Rs. 1,30,00,000 (One Crore Thirty Lakhs Only).	Pharmaceuti cals	1.30
15.	4659	M/s Alphamed Formulations Private Limited	(i) Post facto approval for the transfer of shares to Wisdom Holdings Pte. Ltd. from the existing shareholders of Alphamed Formulations Private Limited (Applicant Company), during the year 2012 and 2013. (ii) Post facto approval for the transfer of shares by Wisdom Holdings Pte. Ltd. in Applicant Company, during the year 2013. (iii) Approval for transfer of equity shares from Wisdom Holdings PTE. LTD to the Acquiring Company. (iv) Approval for transfer of equity shares from Vijya Lakshmi Yakkanti, Neerja Thippabhotla and Viren Khanna to the Acquiring company. (vii) Approval for issue of additional 1,00,00,000 number of equity shares to Aspen Pharmacare Holdings Limited.	Pharmaceuti cals	125.33
16.	4643	M/s Vegesna Laboratories Private Limited	Exit by the resident shareholders of Vegesna Laboratories Private Limited by the sale of 100% equity shares of Vegesna Laboratories Private Limited held by the resident shareholders to American Company Sciegen Pharmaceuticals Inc.	Pharmaceuti cals	12.5

R.J.

**FDI Proposals rejected by Department of Pharmaceuticals (Status as on 31.03.2018)**

S. No.	Proposal No.	Name of the applicant	Gist of the proposal	Sector
1.	4437	M/s Beloor Bayer Biotech Limited	For amendment of FIPB approval No. 24(2016)/111(2014) dated 13.05.2016 by deleting the condition stipulated under para 8(ii) of the approval letter relating to compounding for the period of non-compliance with the FDI Policy for pre-existing FDI in BBTL.	Pharmaceuticals

*[Handwritten signature]*